Dernière mise à jour : 26 juin 2015
Détails
FichiersGeneric Name:
Romidepsin
État du projet:
Terminé
Domaine thérapeutique:
Peripheral T-Cell Lymphoma
Fabricant:
Celgene Inc.
Brand Name:
Istodax
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0048-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
10 mg per vial
Tumour Type:
Lymphoma
Indications:
Peripheral T-Cell Lymphoma
Funding Request:
For patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant and have received at least one prior systemic therapy
Date NOC Issued:
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 26 juin 2015